Generic mifepristone maker GenBioPro seeks to challenge a Mississippi anti-abortion law set into motion by the US Supreme Court’s reversal of Roe v. Wade, claiming the new state of affairs is keeping its product off local shelves.
Mississippi’s trigger law bans the majority of abortions within the state. That includes abortions relying on pills approved by the Food and Drug Administration like mifepristone, which is used to end pregnancies up to 10 weeks.
GenBioPro is now asking the US District Court for the Southern District of Mississippi to amend a complaint it filed in 2020 against the state to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.